View Rule

The FDA is amending its regulations for new animal drugs for investigational use to expand the scope of clinical investigator disqualification to include ineligibility to conduct nonclinical laboratory studies. Under this final rule, when the FDA Commissioner determines that an investigator is ineligible to receive a new animal drug for investigational use, the investigator will be ineligible to conduct both clinical and nonclinical studies intended to support an application for a research or marketing permit for a new animal drug. This final rule will help ensure adequate protection of animal research subjects and the quality and integrity of data submitted to FDA.